Toxicity Profile of Panobinostat as seen in the PANORAMA Trial
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Clinical Pearls:
- In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm.
- A higher rate of thrombocytopenia and other hematological toxicities were also seen in the panobinostat arm.
- However, all of the toxicities were mostly manageable and did not impact the outcome of the trial.
- More details are needed to get a better understanding of the toxicity profile of this combination in this setting.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
